Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of treprostinil palmitil inhalation powder in pulmonary hypertension associated with interstitial lung disease
2021-003294-66Phase 2Completed
- Sponsor
- Insmed Incorporated
- Start
- Mar 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary hypertension associated with interstitial lung disease (PH-ILD) comparing Treprostinil palmitil inhalation powder with Placebo (2 arms). Primary endpoint: Frequency and severity of treatment-emergent adverse events and serious adverse events. Started Mar 2022; status: completed.
02
Drugs
treprostinil palmitil
03
Conditions
pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Beyond the preview
Go deeper on 2021-003294-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003294-66.